First China Pharmaceutical Group (OTCMKTS:FCPG – Get Free Report) and NeoGenomics (NASDAQ:NEO – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.
Profitability
This table compares First China Pharmaceutical Group and NeoGenomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| First China Pharmaceutical Group | N/A | N/A | N/A |
| NeoGenomics | -6.77% | -1.99% | -1.21% |
Earnings and Valuation
This table compares First China Pharmaceutical Group and NeoGenomics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| First China Pharmaceutical Group | N/A | N/A | N/A | N/A | N/A |
| NeoGenomics | $727.33 million | 3.00 | -$108.03 million | ($0.40) | -42.45 |
First China Pharmaceutical Group has higher earnings, but lower revenue than NeoGenomics.
Institutional & Insider Ownership
98.5% of NeoGenomics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for First China Pharmaceutical Group and NeoGenomics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| First China Pharmaceutical Group | 0 | 0 | 0 | 0 | 0.00 |
| NeoGenomics | 1 | 2 | 7 | 1 | 2.73 |
NeoGenomics has a consensus price target of $16.71, indicating a potential downside of 1.56%. Given First China Pharmaceutical Group’s higher possible upside, analysts clearly believe First China Pharmaceutical Group is more favorable than NeoGenomics.
Summary
NeoGenomics beats First China Pharmaceutical Group on 6 of the 10 factors compared between the two stocks.
About First China Pharmaceutical Group
First China Pharmaceutical Group, Inc. operates through its wholly owned subsidiary Kun Ming Xin Yuan Tang Pharmacies Co. Ltd. (XYT) is engaged in drug logistics and distribution in Yunnan Province, China through drug stores, medical clinics and hospitals. XYT is a provincial pharmaceutical distributor that offers approximately 5,000 drugs, of which approximately 1,000 are over-the-counter drugs, approximately 1,000 are prescription drugs, approximately 2,000 are prepared Chinese medicines and approximately 1,000 are supplements. The Company’s short term objective is to broaden its product line from 5,000 products to 30,000 and include significantly more Western medicines as well as traditional Chinese drugs and herbs. By expanding its product line six-fold and offering products at a lower price than major competitors, the Company expects to be able to become its customers’ primary distributor, supplying more than 80% of the pharmaceutical products they require.
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Receive News & Ratings for First China Pharmaceutical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First China Pharmaceutical Group and related companies with MarketBeat.com's FREE daily email newsletter.
